A trial to test if different amounts of KTX-1001 are safe and tolerable in people with the bone marrow cancer multiple myeloma that has come back or where treatment did not work.

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-500801-41-00

Acronym

K36-MMSET-001

Enrollment

Registered

2023-03-06

Start date

2023-07-26

Completion date

Unknown

Last updated

2025-06-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed and Refractory Multiple Myeloma

None listed

Sex/Gender

All

Age

18 Years to No maximum

France, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026